Thermo Fisher Scientific (NYSE:TMO) further expanded its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.
Thermo Fisher sites currently being expanded are: Greenville, NC.; Swindon, U.K.; and Ferentino and Monza, Italy; adding 15 development and cGMP commercial production lines. These projects are expected to be completed over the next two years and will create ~1,000 jobs.
Additionally, company recently announced significant projects in Asia-Pacific, including a new sterile manufacturing facility in Singapore and a new integrated biologics and sterile drug development and manufacturing site in Hangzhou, China.
"With these investments, we've nearly doubled our global footprint for drug development and commercial manufacturing, which allows us to support our customers with unmatched flexibility, expertise and scale at a time of unprecedented demand," commented Mike Shafer, senior vice president and president, pharma services.
